Extension to a Randomized, Double-blind, Placebo Controlled Study of LCQ908 in Subjects With Familial Chylomicronemia Syndrome.

Stopped Interim analysis suggested that size of benefit anticipated from continued participation of patients in Part B no longer supported trial extension beyond Part A

Conditions

• Familial Chylomicronemia Syndrome (FCS) (HLP Type I)

Interventions

• DRUG: LCQ908

Sponsor

Novartis Pharmaceuticals